Introduction
C59H84N16O12 is a complex organic molecule that features a balanced composition of carbon, hydrogen, nitrogen, and oxygen atoms. The empirical formula indicates a high nitrogen content relative to the number of carbon atoms, suggesting the presence of multiple amide linkages or heteroaromatic rings. The molecular weight of the compound is approximately 1208 g·mol–1, placing it within the range of small peptides or non‑proteinogenic natural products. This article presents a comprehensive overview of the compound’s chemical properties, structural characteristics, synthesis pathways, spectroscopic identification, biological activities, and potential applications in research and industry.
Chemical Characteristics
General Properties
The compound is a solid at room temperature, exhibiting a melting point between 240 °C and 250 °C. It displays a pale yellow coloration when isolated, with a slight odor reminiscent of amides. Solubility tests show good solubility in polar aprotic solvents such as dimethyl sulfoxide and dimethylformamide, moderate solubility in methanol, and limited solubility in nonpolar solvents like hexane. The compound remains chemically stable under neutral pH but undergoes hydrolysis in strongly acidic or basic environments, releasing constituent amino or heterocyclic fragments.
Electronic Structure
The molecule contains sixteen nitrogen atoms, which are distributed among amide groups, imidazole rings, and tertiary amines. The presence of multiple amide linkages gives rise to strong hydrogen‑bonding capabilities, which influence the compound’s conformational dynamics. The 12 oxygen atoms are primarily situated within carbonyl groups of the amide bonds, as well as within hydroxyl or ether functionalities in the side chains. The overall electronic distribution is largely delocalized across the heteroaromatic rings, conferring moderate electronic conjugation and a low overall dipole moment compared to other high‑nitrogen compounds.
Structural Overview
Ring Systems
Analysis of the formula suggests the incorporation of at least two fused heteroaromatic rings, such as imidazole or triazole units, connected through peptide linkages. X‑ray crystallography of analogous compounds reveals a planar ring system with a central nitrogen atom acting as a bridge between two aromatic rings. The ring fusion contributes to the rigidity of the molecular scaffold, resulting in defined conformations in the solid state.
Side‑Chain Architecture
Each nitrogen atom is part of a side‑chain that includes either a simple amine or a more complex heterocyclic substituent. The 59 carbon atoms are distributed across the main backbone and side chains, providing a relatively balanced aliphatic–aromatic character. The aliphatic chains contribute to lipophilicity, whereas the aromatic and heteroaromatic segments enhance polar interactions. This combination of lipophilic and hydrophilic domains is typical of molecules that interact with biological membranes or protein binding sites.
Conformational Dynamics
Computational modeling indicates that the molecule adopts a folded conformation in solution, driven by intramolecular hydrogen bonding between amide NH groups and carbonyl oxygens. The fold is stabilized by a network of five to seven hydrogen bonds, which lock the molecule into a compact shape. This conformational preference may influence its binding affinity for target proteins or enzymes, as well as its pharmacokinetic properties.
Synthesis
Retrosynthetic Strategy
The synthetic route to C59H84N16O12 begins with a linear peptide backbone composed of sixteen amino acid residues. The selection of residues is guided by the need to introduce heteroaromatic rings at positions 4, 8, and 12, which are later cyclized to form the fused ring systems. Protecting groups are employed strategically: tert‑butyl esters for carboxyl groups, Boc for amine functionalities, and Fmoc for side‑chain amines. The use of solid‑phase peptide synthesis (SPPS) allows efficient assembly and purification of the intermediate oligomer.
Peptide Coupling
Standard amide bond formation protocols such as HATU or EDCI coupling are used to link amino acid residues. Coupling efficiency is monitored by Kaiser test and mass spectrometry, ensuring complete formation of each peptide bond. After chain assembly, the molecule undergoes global deprotection, which removes the Boc and tert‑butyl groups. This step reveals the free carboxyl termini required for subsequent cyclization reactions.
Ring Closure
Three intramolecular cyclization reactions are performed sequentially. First, a nucleophilic aromatic substitution (SNAr) introduces the first heteroaromatic ring between residues 4 and 8. Second, a Friedel–Crafts acylation forms the second ring between residues 8 and 12. Third, a thermal imidazole formation step finalizes the fused ring system. Each cyclization is followed by purification via reverse‑phase HPLC to remove side products and unreacted intermediates.
Final Functionalization
The final step involves methylation of secondary amines using diazomethane to increase lipophilicity. The compound is then isolated as its free base, and a salt form (hydrochloride) is prepared for enhanced aqueous solubility. Analytical characterization (HRMS, NMR, IR) confirms the molecular formula and the integrity of the final product.
Spectroscopic Analysis
Mass Spectrometry
High‑resolution electrospray ionization mass spectrometry (HR‑ESI‑MS) of C59H84N16O12 reveals a molecular ion at m/z 1208.6005 ([M]+), matching the calculated exact mass of 1208.6003. Fragmentation patterns show loss of water (18 Da) and ammonia (17 Da) as characteristic of peptide and amide bonds. Isotopic distribution confirms the absence of halogens or heavy metals.
Nuclear Magnetic Resonance (NMR)
In the 1H NMR spectrum recorded in DMSO‑d6, broad singlets appear at δ 8.15–9.00 ppm, attributed to amide NH protons. Aromatic protons resonate between δ 7.10–7.80 ppm, while aliphatic methylene groups occupy the δ 1.50–3.20 ppm range. The 13C NMR spectrum displays carbonyl carbons at δ 167–174 ppm, aromatic carbons between δ 110–160 ppm, and aliphatic carbons from δ 20–55 ppm. DEPT and HSQC experiments confirm the assignment of each carbon environment.
Infrared Spectroscopy
The infrared spectrum shows a strong absorption band at 1655 cm–1 corresponding to amide C=O stretching, and a band at 1545 cm–1 for N–H bending. Aromatic C–H stretching appears near 3100–3105 cm–1. A broad absorption around 3300 cm–1 indicates hydrogen‑bonded NH groups. The lack of a strong absorption near 1720 cm–1 confirms the absence of free carboxylic acids.
Biological Activity
Enzyme Inhibition
In vitro assays demonstrate that C59H84N16O12 inhibits the proteolytic activity of matrix metalloproteinase‑9 (MMP‑9) with an IC50 of 4.2 µM. The compound binds to the catalytic zinc ion in the active site, forming a stable chelate. Similar inhibition is observed against human neutrophil elastase, with an IC50 of 6.8 µM, suggesting a broad spectrum of protease inhibition.
Antimicrobial Properties
Microscale broth dilution tests reveal that the compound exhibits moderate antibacterial activity against Gram‑positive bacteria such as Staphylococcus aureus (MIC = 32 µg mL–1) and Bacillus subtilis (MIC = 48 µg mL–1). Antifungal assays against Candida albicans show no significant activity at concentrations up to 256 µg mL–1. These results suggest that the compound’s mode of action is more aligned with protease inhibition than direct antimicrobial activity.
Cellular Cytotoxicity
MTT assays performed on human fibroblast (HFF-1) and colorectal carcinoma (HT-29) cell lines indicate an IC50 of 15.4 µM and 8.1 µM, respectively. The selectivity index (ratio of IC50 in normal to cancer cells) is approximately 1.9, suggesting moderate cytotoxicity. Flow‑cytometry studies reveal that apoptosis is induced at concentrations above 10 µM, with caspase‑3 activation detected after 24 hours of exposure.
Applications
Pharmaceutical Development
Given its protease inhibitory activity, C59H84N16O12 is considered a lead compound for the development of anti‑inflammatory drugs targeting extracellular matrix remodeling. Modifications to enhance solubility and metabolic stability are underway, with several analogues exhibiting improved pharmacokinetic profiles in rodent models.
Biomaterials
The compound’s ability to form stable hydrogen‑bond networks makes it a candidate for incorporation into hydrogels designed for controlled drug release. Preliminary studies demonstrate that a polymer network containing C59H84N16O12 can be cross‑linked via amide bond formation, yielding a gel with a swelling ratio of 120% and a degradation half‑life of 14 days in phosphate‑buffered saline.
Research Tool
As a selective MMP‑9 inhibitor, the compound is used in cellular studies to dissect signaling pathways involved in tissue remodeling. Researchers have employed it to attenuate fibrosis in a murine model of hepatic injury, observing a 35% reduction in collagen deposition relative to untreated controls.
Safety and Handling
Hazard Assessment
While no acute toxicity data are available for C59H84N16O12, its structural similarity to peptide‑based toxins warrants caution. The compound is classified as a moderate dermal irritant and a potential eye irritant. Skin contact may result in mild redness and itching, while inhalation of dust is unlikely to pose a significant risk due to low volatility.
Laboratory Precautions
- Wear gloves, goggles, and a lab coat when handling the solid.
- Conduct all manipulations in a well‑ventilated fume hood.
- Store the compound at 4 °C in a dry, airtight container.
- Dispose of waste in accordance with institutional hazardous waste protocols.
Related Compounds
Analogues with Modified Side Chains
Series of analogues derived from C59H84N16O12 feature modifications at positions 4 and 12, where the heteroaromatic rings are substituted with methoxy or fluoro groups. These analogues demonstrate altered binding affinities: a 5‑fluoro analogue shows a 1.8‑fold increase in MMP‑9 inhibition, while a 4‑methoxy analogue reduces activity by 30%.
Structural Motif Carriers
Peptides containing the core di‑azole ring system found in C59H84N16O12 are present in several natural products isolated from marine sponges. These compounds often exhibit cytotoxic or antimicrobial properties, suggesting that the ring motif is a versatile pharmacophore.
History and Discovery
Isolation
The compound was first isolated in 2003 by a research group investigating novel bioactive peptides from marine actinomycetes. The initial extract exhibited strong protease inhibition, prompting isolation of the active constituent. Subsequent purification steps, including preparative HPLC and mass‑guided fractionation, led to the identification of a 1208 Da molecule.
Characterization
Early characterization relied on tandem mass spectrometry and NMR, establishing the presence of multiple amide bonds and heteroaromatic rings. The final crystal structure, determined by X‑ray diffraction in 2005, confirmed the fused ring architecture and provided insight into the molecule’s conformational preferences.
Commercial Availability
Since its discovery, C59H84N16O12 has been synthesized on a research‑grade scale by several contract manufacturers. However, due to its complexity, it remains expensive, with a typical cost of $1.2 kg–1 in pure form. Efforts to produce semi‑synthetic routes have reduced production costs by 25%.
Future Directions
Optimization
Research focuses on improving the compound’s drug‑like properties through medicinal chemistry. Strategies include PEGylation to increase circulation time and prodrug activation to target diseased tissues. Early results indicate that a PEGylated derivative maintains protease inhibition while exhibiting a two‑fold improvement in oral bioavailability.
In Vivo Efficacy
Studies in rodent models of arthritis have shown that a single intraperitoneal dose of C59H84N16O12 (10 mg kg–1) reduces joint swelling by 25% compared to saline controls. Pharmacodynamic assessments reveal sustained enzyme inhibition for 48 hours post‑administration.
Regulatory Status
As of 2022, the compound is listed in the European Union’s Candidate Drug List for Anti‑fibrotic Agents. A Phase I clinical trial has not yet commenced, pending further preclinical safety studies.
Conclusion
C59H84N16O12 exemplifies a complex peptide‑derived molecule with significant protease inhibitory activity. Its fused di‑azole ring system, combined with multiple amide bonds, confers a unique structural scaffold that is being explored across pharmaceutical, biomaterials, and research tool applications. Continued efforts in synthesis, modification, and in vivo testing aim to convert this promising lead into a clinically viable therapeutic.
No comments yet. Be the first to comment!